牛牛AI助理已提取核心訊息
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the fourth quarter and fiscal year ended December 31, 2023, on February 8, 2024. The company announced a 4% increase in Q4 revenue to $1.12 billion compared to the same period in 2022, and a 2% decrease in annual revenue to $4.50 billion. Despite shipping 79 NovaSeq X instruments in Q4 and 352 in the fiscal year, Illumina experienced a GAAP diluted loss per share of $(1.11) for Q4 and $(7.34) for the fiscal year, which included significant goodwill and intangible impairments related to the GRAIL segment. Non-GAAP diluted earnings per share remained stable at $0.14 for Q4 and decreased to $0.86 for the fiscal year. Illumina also announced its intention to divest GRAIL, aiming to finalize terms by the end of Q2 2024, in compliance with the European Commission's divestiture order. The company's financial outlook for fiscal year 2024 anticipates approximately flat Core Illumina revenue compared to 2023 and a Core Illumina non-GAAP operating margin of around 20%.
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, reported its financial results for the fourth quarter and fiscal year ended December 31, 2023, on February 8, 2024. The company announced a 4% increase in Q4 revenue to $1.12 billion compared to the same period in 2022, and a 2% decrease in annual revenue to $4.50 billion. Despite shipping 79 NovaSeq X instruments in Q4 and 352 in the fiscal year, Illumina experienced a GAAP diluted loss per share of $(1.11) for Q4 and $(7.34) for the fiscal year, which included significant goodwill and intangible impairments related to the GRAIL segment. Non-GAAP diluted earnings per share remained stable at $0.14 for Q4 and decreased to $0.86 for the fiscal year. Illumina also announced its intention to divest GRAIL, aiming to finalize terms by the end of Q2 2024, in compliance with the European Commission's divestiture order. The company's financial outlook for fiscal year 2024 anticipates approximately flat Core Illumina revenue compared to 2023 and a Core Illumina non-GAAP operating margin of around 20%.
DNA測序和基於陣列的技術領域的全球領導者Illumina, Inc. 於2024年2月8日公佈了截至2023年12月31日的第四季度和財年的財務業績。該公司宣佈，與2022年同期相比，第四季度收入增長4％，至11.2億美元，年收入下降2％，至45.0億美元。儘管第四季度出貨了79只NovaSeq X工具，在本財年出貨了352種，但Illumina第四季度的GAAP攤薄後每股虧損爲1.11美元，本財年度的攤薄後每股虧損爲7.34美元，其中包括與GRAIL板塊相關的重大商譽和無形減值。第四季度非公認會計准則攤薄後每股收益穩定在0.14美元，本財年降至0.86美元。Illumina還宣佈打算剝離GRAIL，目標是根據歐盟委員會的剝離令，在2024年第二季度末之前敲定條款。該公司2024財年的財務展望預計，與2023年相比，Core Illumina的收入將基本持平，Core Illumina的非公認會計准則營業利潤率約爲20％。
DNA測序和基於陣列的技術領域的全球領導者Illumina, Inc. 於2024年2月8日公佈了截至2023年12月31日的第四季度和財年的財務業績。該公司宣佈，與2022年同期相比，第四季度收入增長4％，至11.2億美元，年收入下降2％，至45.0億美元。儘管第四季度出貨了79只NovaSeq X工具，在本財年出貨了352種，但Illumina第四季度的GAAP攤薄後每股虧損爲1.11美元，本財年度的攤薄後每股虧損爲7.34美元，其中包括與GRAIL板塊相關的重大商譽和無形減值。第四季度非公認會計准則攤薄後每股收益穩定在0.14美元，本財年降至0.86美元。Illumina還宣佈打算剝離GRAIL，目標是根據歐盟委員會的剝離令，在2024年第二季度末之前敲定條款。該公司2024財年的財務展望預計，與2023年相比，Core Illumina的收入將基本持平，Core Illumina的非公認會計准則營業利潤率約爲20％。
有用
沒用
